Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5637034 | 0.86 | KMT2A (0.49) | NPC1KMT2ASMN1; SMN2RAB9AGAA | |
| SCHEMBL5640329 | 0.86 | SMN1; SMN2 (0.46) | NPC1KMT2ASMN1; SMN2RAB9AMEN1 | |
| SCHEMBL5637671 | 0.86 | NPC1 (0.53) | NPC1KMT2ASMN1; SMN2RAB9AMEN1 | |
| SCHEMBL5638355 | 0.85 | NPC1 (0.49) | NPC1KMT2ASMN1; SMN2RAB9AMEN1 | |
| SCHEMBL5638456 | 0.82 | NPC1 (0.50) | NPC1KMT2ASMN1; SMN2RAB9AMEN1 | |
| SCHEMBL5638422 | 0.80 | KMT2A (0.43) | NPC1KMT2ASMN1; SMN2RAB9AMEN1 | |
| SCHEMBL5638857 | 0.80 | NPC1 (0.49) | NPC1KMT2ASMN1; SMN2RAB9AGAA | |
| SCHEMBL5638120 | 0.74 | ALDH1A1 (0.38) | KMT2ASMN1; SMN2RAB9AGAAMAPT | |
| SCHEMBL5637705 | 0.73 | POLB (0.35) | ALDH1A1 | |
| SCHEMBL5637024 | 0.73 | POLB (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | NPC1 449/4885KMT2A 3541/4885SMN1; SMN2 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.